← All trials
NCT04377126
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 20, 2020
- Primary completion
- Jun 1, 2022
- Completion date
- Jun 1, 2023
- First posted
- May 6, 2020
- Last posted
- May 6, 2020
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Northwestern UniversityLead sponsor
- Northwestern UniversityOverall official - principal investigator
- Northwestern UniversityReponsible party - principal investigator
- National Institute on Aging (NIA)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.